NASDAQ: $INO New Hope for Patients with Dystrophic Epidermolysis Bullosa The medical community is celebrating a significant milestone in genetic medicine. The U.S. Food and Drug Administration (FDA) has officially granted accelerated approval to Voceryq (beremagene geperpavec-svdt), a transformative gene therapy designed to treat wounds in patients aged 6 months and older with dystrophic epidermolysis…